Galapagos NV (Galapagos) is a biotechnology company that discovers and develops small-molecule medicines for the treatment of inflammatory and fibrotic diseases. It offers Filgotinib medication targeting rheumatoid arthritis (RA). The company is investigating the GLPG3667 compound against autoimmune indications. The company offers its products in the therapeutic areas of immunology and oncology. It partners with academic organizations and universities to accelerate development and boost innovation in discovery, preclinical and clinical development. The company operates in Belgium, the Netherlands, France, Germany, Austria, Italy, Spain, the Nordics, Switzerland, the UK and the US. Galapagos is headquartered in Mechelen, Belgium.
Galapagos NV premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Filgotinib |
3667 |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In January, the company and Thermo Fisher Scientific entered into a partnership for the decentralized manufacturing of its point-of-care CAR-T product candidate in San Francisco. |
2024 | Contracts/Agreements | In January, the company and BridGene Biosciences entered into a strategic collaboration and licensing agreement to develop and discover new precision medicines against clinically validated oncology targets. |
2024 | Contracts/Agreements | In January, the company signed an agreement to sell its Jyseleca (filgotinib) business to Alfasigma S.p.A. |
Competitor Comparison
Key Parameters | Galapagos NV | Mithra Pharmaceuticals SA | TherapeuticsMD Inc | Oxurion NV | Ablynx NV |
---|---|---|---|---|---|
Headquarters | Belgium | Belgium | United States of America | Belgium | Belgium |
City | Malines (Mechelen) | Liege | Boca Raton | Leuven (Louvain) | Ghent |
State/Province | - | Liege | Florida | - | Flandre Orientale |
No. of Employees | 1,233 | 229 | 1 | 27 | 450 |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Paul Stoffels | Chief Executive Officer; Chairman | Executive Board | 2022 | - |
Thad Huston | Chief Operating Officer; Chief Financial Officer | Senior Management | 2023 | - |
Philippe Alen | Senior Vice President; Head - Business Development | Senior Management | 2022 | - |
Pierre Raboisson | Head - Discovery | Senior Management | 2022 | - |
John Mellors | Head - Cell and Antibody-Therapy Discovery | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward